Amiselimod
As of the edition of 20 October 2026, Amiselimod is a small molecule: in active development; acts on S1PR1, S1PR2 and S1PR3 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2015
- Kind
- Small molecule
- Registered trials
- 11, 0 stopped early
- Disease areas
- Digestive system; Immune system; Nervous system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 6 | 6 | 0 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tanabe Pharma | Lead sponsor of trials | 2014 to now |
| Bausch Health | Lead sponsor of trials | 2021 to now |